Niagen Bioscience/$NAGE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Niagen Bioscience
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
Ticker
$NAGE
Sector
Primary listing
Employees
117
Headquarters
Website
NAGE Metrics
BasicAdvanced
$271m
16.19
$0.21
2.06
-
Price and volume
Market cap
$271m
Beta
2.06
52-week high
$11.29
52-week low
$3.12
Average daily volume
731k
Financial strength
Current ratio
4.606
Quick ratio
3.482
Long term debt to equity
1.875
Total debt to equity
3.129
Profitability
EBITDA (TTM)
11.981
Gross margin (TTM)
64.28%
Net profit margin (TTM)
14.29%
Operating margin (TTM)
8.51%
Effective tax rate (TTM)
5.38%
Revenue per employee (TTM)
$1,110,000
Management effectiveness
Return on assets (TTM)
7.09%
Return on equity (TTM)
27.07%
Valuation
Price to earnings (TTM)
16.189
Price to revenue (TTM)
2.078
Price to book
3.29
Price to tangible book (TTM)
3.52
Price to free cash flow (TTM)
66
Free cash flow yield (TTM)
1.52%
Free cash flow per share (TTM)
0.052
Growth
Revenue change (TTM)
20.84%
Earnings per share change (TTM)
17.35%
3-year revenue growth (CAGR)
19.02%
10-year revenue growth (CAGR)
18.40%
3-year earnings per share growth (CAGR)
11.20%
10-year earnings per share growth (CAGR)
17.65%
What the Analysts think about NAGE
Analyst ratings (Buy, Hold, Sell) for Niagen Bioscience stock.
NAGE Financial Performance
Revenues and expenses
NAGE Earnings Performance
Company profitability
NAGE News
AllArticlesVideos
Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
Business Wire·4 hours ago
Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biological Aging
Business Wire·6 days ago
Niagen Bioscience to Present at Canaccord Genuity's 46th Annual Growth Conference
Business Wire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.